Enoblituzumab 是一种人源化IgG1κ单克隆抗体，可以识别人B7-H3蛋白 (B7 家族的免疫调节剂成员)。
| 生物活性 | Enoblituzumab (MGA271) is a humanizedIgG1κmonoclonal antibody recognizing humanB7-H3protein, a member of the B7 family of immune regulators[1]. |
体外研究
(In Vitro) | Enoblituzumab interacts with B7-H3 and causes strong antibody-dependent cellular cytotoxicity (ADCC) against a wide spectrum of cancer cells[2].
Enoblituzumab (0.01 ng/mL-10 mg/mL) mediates antibody-dependent cellular cytotoxicity (ADCC) against A498 cells with cynomolgus monkey peripheral blood mononuclear cells (PBMCs)[3].
|
体内研究
(In Vivo) | Enoblituzumab (5 mg/kg; i.v.; single dose) exhibits estimated half-life of 249 hours with a Cmaxof 43 mg/mL in mice (mCD16-/-hCD16A+) that murine CD16 gene knocked out and are transgenic for human CD16A-158F[3].
Enoblituzumab (0.1-10 mg/kg; i.v.; once weekly; 5 weeks) exhibits potent antitumor activity in B7-H3-expressing xenograft mice models of renal cell and bladder carcinoma[3].
| Animal Model: | mCD16-/-hCD16A+mice implanted with A498 renal cell carcinoma, 786-0 renal cell carcinoma, or HT-1197 bladder carcinoma cells (s.c.)[3] | | Dosage: | 1 mg/kg, 5 mg/kg, 10 mg/kg | | Administration: | Intravenous injection; once weekly; 5 weeks | | Result: | Significantly inhibited tumor growth at doses of 1 mg/kg or greater with once weekly treatment.
Achieved a cytostatic response at 5 or 10 mg/kg until day 52, after which the average tumor volume of the 5 mg/kg treatment group remained near predose administration levels, whereas a nonsignificant trend toward relapse exhibited in the 10 mg/kg group. |
|
| Clinical Trial | |
| 性状 | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
